{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:54:21Z","timestamp":1785596061520,"version":"3.56.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00277-024-05845-2","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T02:01:41Z","timestamp":1727402501000},"page":"4497-4502","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Increased trough concentration of venetoclax when combined with itraconazole for acute myeloid leukemia"],"prefix":"10.1007","volume":"103","author":[{"given":"Masao","family":"Hagihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Yasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Gando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomiyuki","family":"Sugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morihiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"5845_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Dohner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hajek R, Porkka K, Illes A, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629","journal-title":"N Engl J Med"},{"key":"5845_CR2","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1182\/bloodadvances.2019000930","volume":"3","author":"I Aldoss","year":"2019","unstructured":"Aldoss I, Dadwal S, Zhang J, Tegtmeier B, Mei M, Arslan S, Al Malki MM, Salhotra A, Ali H, Aribi A, Sandhu K, Khaled S, Snyder D, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V (2019) Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv 3:4043\u20134049","journal-title":"Blood Adv"},{"key":"5845_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bjh.18051","volume":"197","author":"S On","year":"2022","unstructured":"On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, Alegria W, Young R, Tan M, Kim C, Phun J, Patel N, Mannis G, Logan AC, Kennedy V, Goodman A, Taplitz RA, Young PA, Wen R, Saunders IM (2022) Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. Br J Haematol 197:63\u201370","journal-title":"Br J Haematol"},{"key":"5845_CR4","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/jac\/dkad143","volume":"78","author":"J Stemler","year":"2023","unstructured":"Stemler J, Mellinghoff SC, Khodamoradi Y, Sprute R, Classen AY, Zapke SE, Hoenigl M, Krause R, Schmidt-Hieber M, Heinz WJ, Klein M, Koehler P, Liss B, Koldehoff M, Buhl C, Penack O, Maschmeyer G, Schalk E, Lass-Florl C, Karthaus M, Ruhnke M, Cornely OA, Teschner D (2023) Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the infectious diseases working party (agiho) of the German society for haematology and medical oncology (dgho). J Antimicrob Chemother 78:1813\u20131826","journal-title":"J Antimicrob Chemother"},{"key":"5845_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/myc.13129","volume":"63","author":"Y Hamada","year":"2020","unstructured":"Hamada Y, Ueda T, Miyazaki Y, Nakajima K, Fukunaga K, Miyazaki T, Nakada-Motokawa N, Nagao M, Kawamura H, Shigemi A, Ebihara F, Kimura T, Ikegame K, Uchino M, Ikeuchi H, Takesue Y (2020) Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: a multicentre study conducted in Japan. Mycoses 63:779\u2013786","journal-title":"Mycoses"},{"key":"5845_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hon.2964","volume":"40","author":"D Brackman","year":"2022","unstructured":"Brackman D, Eckert D, Menon R, Salem AH, Potluri J, Smith BD, Wei AH, Hayslip J, Miles D, Mensing S, Gopalakrishnan S, Zha J (2022) Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naive acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematol Oncol 40:269\u2013279","journal-title":"Hematol Oncol"},{"key":"5845_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/jcph.858","volume":"57","author":"KJ Freise","year":"2017","unstructured":"Freise KJ, Shebley M, Salem AH (2017) Quantitative prediction of the effect of cyp3a inhibitors and inducers on venetoclax pharmacokinetics using a physiologically based pharmacokinetic model. J Clin Pharmacol 57:796\u2013804","journal-title":"J Clin Pharmacol"},{"key":"5845_CR8","doi-asserted-by":"publisher","first-page":"107373","DOI":"10.1016\/j.leukres.2023.107373","volume":"133","author":"F De la Garza-Salazar","year":"2023","unstructured":"De la Garza-Salazar F, Colunga-Pedraza PR, Gomez-Almaguer D, Garcia-Zarate VA, Gomez-De Leon A (2023) Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: a phase 2 study. Leuk Res 133:107373","journal-title":"Leuk Res"},{"key":"5845_CR9","doi-asserted-by":"publisher","first-page":"E422","DOI":"10.1002\/ajh.26707","volume":"97","author":"BA Jonas","year":"2022","unstructured":"Jonas BA, DiNardo C, Fracchiolla N, Pristupa A, Ishizawa K, Jin J, Konopleva M, Ofran Y, Montesinos P, Kovacsovics T, Jang JH, Kantarjian H, Duan Y, Potluri J, Werner M, Pratz KW (2022) Use of cyp3ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the viale-a study. Am J Hematol 97:E422\u2013E425","journal-title":"Am J Hematol"},{"key":"5845_CR10","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/chromsci\/bmac027","volume":"61","author":"T Yasu","year":"2023","unstructured":"Yasu T, Gando Y, Nomura Y, Kosugi N, Kobayashi M (2023) Determination of venetoclax concentration in plasma using high-performance liquid chromatography. J Chromatogr Sci 61:480\u2013483","journal-title":"J Chromatogr Sci"},{"key":"5845_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-022-01229-z","volume":"15","author":"NJ Short","year":"2022","unstructured":"Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian H (2022) Impact of frontline treatment approach on outcomes in patients with secondary aml with prior hypomethylating agent exposure. J Hematol Oncol 15:12","journal-title":"J Hematol Oncol"},{"key":"5845_CR12","doi-asserted-by":"crossref","unstructured":"Garciaz S, Hospital MA, Alary AS, Saillard C, Hicheri Y, Mohty B, Rey J, D\u2019Incan E, Charbonnier A, Villetard F, Maisano V, Lombardi L, Ittel A, Mozziconacci MJ, Gelsi-Boyer V, Vey N (2022) Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients. Cancers (Basel) 14","DOI":"10.3390\/cancers14082025"},{"key":"5845_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2019001239","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Wei AH (2020) How i treat acute myeloid leukemia in the era of new drugs. Blood 135:85\u201396","journal-title":"Blood"},{"key":"5845_CR14","doi-asserted-by":"crossref","unstructured":"De Gregori S, Gelli E, Capone M, Gambini G, Roncoroni E, Rossi M, Tobar Cabrera CP, Martini G, Calabretta L, Arcaini L, Albertini R, Zappasodi P (2023) Pharmacokinetics of venetoclax co-administered with posaconazole in patients with acute myeloid leukemia. Pharmaceutics 15","DOI":"10.3390\/pharmaceutics15061680"},{"key":"5845_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, Wong SL, Menon RM, Konopleva MY, Salem AH (2017) Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther 39:359\u2013367","journal-title":"Clin Ther"},{"key":"5845_CR16","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1128\/AAC.44.7.1887-1893.2000","volume":"44","author":"JL Harousseau","year":"2000","unstructured":"Harousseau JL, Dekker AW, Stamatoullas-Bastard A, Fassas A, Linkesch W, Gouveia J, De Bock R, Rovira M, Seifert WF, Joosen H, Peeters M, De Beule K (2000) Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin b. Antimicrob Agents Chemother 44:1887\u20131893","journal-title":"Antimicrob Agents Chemother"},{"key":"5845_CR17","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1248\/bpb.33.1861","volume":"33","author":"S Shimoeda","year":"2010","unstructured":"Shimoeda S, Nakagawa S, Kobayashi H, Yamato S, Kawano K, Ohta S (2010) Clinical significance of measuring the blood concentration of itraconazole oral solution in the field of hematology. Biol Pharm Bull 33:1861\u20131866","journal-title":"Biol Pharm Bull"},{"key":"5845_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12032-022-01865-y","volume":"39","author":"M Kobayashi","year":"2022","unstructured":"Kobayashi M, Yasu T, Suzaki K, Kosugi N (2022) Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia. Med Oncol 39:259","journal-title":"Med Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05845-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05845-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05845-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T01:05:45Z","timestamp":1730855145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05845-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["5845"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05845-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained by the Institutional committee of Eiju General Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent to publish was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}